Literature DB >> 24532765

Effectiveness of switching between biologics in psoriatic arthritis- results of a large regional survey.

Meghna Jani1, Elizabeth Macphie, Chandani Rao, Sarah Moore, Hoda Mirjafari, Yokemie McLoughlin, Hector Chinoy, Preeti Shah.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24532765      PMCID： PMC5873642          DOI： 10.7861/clinmedicine.14-1-95

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


× No keyword cloud information.
  4 in total

1.  The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.

Authors:  Laura C Coates; William Tillett; David Chandler; Philip S Helliwell; Eleanor Korendowych; Stuart Kyle; Iain B McInnes; Susan Oliver; Anthony Ormerod; Catherine Smith; Deborah Symmons; Nicola Waldron; Neil J McHugh
Journal:  Rheumatology (Oxford)       Date:  2013-07-25       Impact factor: 7.580

2.  Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.

Authors:  Bente Glintborg; Mikkel Ostergaard; Niels Steen Krogh; Martin Dehn Andersen; Ulrik Tarp; Anne Gitte Loft; Hanne M Lindegaard; Mette Holland-Fischer; Henrik Nordin; Dorte Vendelbo Jensen; Christian Holkmann Olsen; Merete Lund Hetland
Journal:  Arthritis Rheum       Date:  2013-05

3.  European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.

Authors:  L Gossec; J S Smolen; C Gaujoux-Viala; Z Ash; H Marzo-Ortega; D van der Heijde; O FitzGerald; D Aletaha; P Balint; D Boumpas; J Braun; F C Breedveld; G Burmester; J D Cañete; M de Wit; H Dagfinrud; K de Vlam; M Dougados; P Helliwell; A Kavanaugh; T K Kvien; R Landewé; T Luger; M Maccarone; D McGonagle; N McHugh; I B McInnes; C Ritchlin; J Sieper; P P Tak; G Valesini; J Vencovsky; K L Winthrop; A Zink; P Emery
Journal:  Ann Rheum Dis       Date:  2011-09-27       Impact factor: 19.103

4.  The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients.

Authors:  Chamaida Plasencia; Dora Pascual-Salcedo; Sara García-Carazo; Leticia Lojo; Laura Nuño; Alejandro Villalba; Diana Peiteado; Florencia Arribas; Jesus Díez; Maria Teresa López-Casla; Emilio Martín-Mola; Alejandro Balsa
Journal:  Arthritis Res Ther       Date:  2013-07-26       Impact factor: 5.156
  4 in total
  3 in total

1.  Long-term effectiveness of tumour necrosis factor-α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study.

Authors:  Gavin Clunie; Iain B McInnes; Nick Barkham; Helena Marzo-Ortega; Yusuf Patel; Andrew Gough; Jon Packham; Stuart Kyle; Bruce Kirkham; Tom Sheeran; Helen Coope; Anna Bishop-Bailey; Neil McHugh
Journal:  Rheumatol Adv Pract       Date:  2018-10-17

Review 2.  Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence.

Authors:  Luisa Costa; Carlo Perricone; Maria Sole Chimenti; Antonio Del Puente; Paolo Caso; Rosario Peluso; Paolo Bottiglieri; Raffaele Scarpa; Francesco Caso
Journal:  Drugs R D       Date:  2017-12

3.  Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis.

Authors:  Yan Song; Keith A Betts; Yichen Lu; Rakesh Singh; Jerry Clewell; Jenny Griffith
Journal:  Rheumatol Ther       Date:  2019-05-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.